A prospective observational comparative study of effectiveness and adverse effects of amitriptyline versus duloxetine in the treatment of somatoform pain disorders in a tertiary care hospital

Nagabushan H.; P. Monika; Bhagyavathi  H. D.

doi:10.18203/2319-2003.ijbcp20243829

Authors

Nagabushan H. Department of Pharmacology, MIMS, Mandya, Karnataka, India
P. Monika Department of Pharmacology, MIMS, Mandya, Karnataka, India
Bhagyavathi H. D. Department of Psychiatry, MIMS, Mandya, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20243829

Keywords:

Amitriptyline, Duloxetine, Effectiveness, Somatoform, Safety

Abstract

Background: To compare the effectiveness and adverse effects as well as treatment compliance of amitriptyline and duloxetine in treating somatoform pain disorder.

Methods: This study was done on 100 patients, with 50 in each group, at Mandya Institute of Medical Sciences (MIMS) over 6 months. Group A was treated with amitriptyline 75 mg per day, and Group B with duloxetine 40 mg per day. Patient Health Questionnaire (PHQ-15) as well as Social and Occupational Functional Assessment Score (SOFAS) were used to compare effectiveness of treatment. For medication adherence Medication Adherence Rating Scale (MARS) was used. Adverse effects were also monitored. The baseline measurements were taken, and evaluations were conducted at 4th, 8th, and 12th weeks of follow-up.

Results: There were 31% males and 69% females. At baseline and after 12 weeks, Group A had average PHQ-15 scores of 14.72±6.13 and 3.16±0.97, respectively, while group B had scores of 17.12±5.45 and 7.22±2.46. During the same period SOFAS scores were 48.70±6.27 and 85.9±5.06 for group A, and 50.86±5.99 and 82.62±6.10 for group B. The effectiveness of Amitriptyline group showed statistically significant difference (p<0.05) when compared with Duloxetine. Group A experienced more adverse effects like dry mouth, drowsiness when compared to Group B.

Conclusions: Amitriptyline and duloxetine are effective in treatment of somatoform pain disorder; the effectiveness of amitriptyline was higher when compared to duloxetine in our study.

Metrics

Metrics Loading ...

References

Agarwal V, Nischal A, Praharaj SK, Menon V, Kar SK. Clinical practice guideline: psychotherapies for somatoform disorders. Ind J Psychi. 2020;62(2):263-71.

Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341(18):1329-35.

O’Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999;48(12):980-90.

Volz HP, Murck H, Kasper S, Möller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacol (Berl). 2002;164(3):294-300.

Müller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med. 2004;66(4):538547.

Liu Y, Zhao J, Fan X, Guo W. Dysfunction in serotonergic and noradrenergic systems and somatic symptoms in psychiatric disorders. Front Psychiatry. 2019;10:286.

Richardson BP. Serotonin and nociception. Ann N Y Acad Sci. 1990;600:511-9.

Jones SL. Descending noradrenergic influences on pain. Prog Brain Res. 1991;88: 381-394.

Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry. 2002;63(5):382-3.

Dinan TG, Barry S, Ahkion S, Chua A, Keeling PW. Assessment of central noradrenergic functioning in irritable bowel syndrome using a neuroendocrine challenge test. J Psychosom Res. 1990;34(5):575-80.

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-15.

Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36(6):383-90.

Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med. 2007;69(9):8818-81.

Somashekar B, Jainer A, Wuntakal B: Psychopharmacotherapy of somatic symptoms disorders. Int Rev Psychiatry. 2013:25:107-15.

Sardesai A, Muneshwar K N, Bhardwaj M, et al. The importance of early diagnosis of somatic symptom disorder: a case report. Cureus 2023;15(9):44554

Joshi S, Pandey AK, Sapkota N. Efficacy and tolerability of Amitriptyline versus Fluoxetine in the treatment of patients with somatoform disorder: A randomized comparative trial. J Psyc Asso of Nepal. 2015;4(2):10-5.

Pokhrel R, Rajbhandari N, Sah S, Kathet R, Sah P, Karn S. Effectiveness of duloxetine in treating early stage of somatoform disorder at Koshi zonal hospital. BJHS. 2019;4(1)8:602-6.

Skljarevski V, Ossanna M, Liu-Seifert H. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16(9):1041–8.

García-Marn I, Miranda-Vicario EM, Soutullo CA. Duloxetine in the treatment of adolescents with somatoform disorders: a report of two cases. Actas Esp Psiquiatr. 2012;40(3):165-8.

Sullivan MD, Bentley S, Fan MY, Gardner G. A single-blind, placebo run-in study of duloxetine for activity-liming osteoarthritis pain. J Pain. 2009;10(2):208-13.

Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34(4):818-22.

Sumedhan SV, Wilson V, Manoj P, Rajamony PN. Effectiveness and safety of amitriptyline, duloxetine, and pregabalin in painful diabetic neuropathy: An observational study. Natl J Physiol Pharm Pharmacol. 2023;13(7):1374-9.

Kamal MM, Rahman MM, Sharmin S, Bhowmick DK, Islam MS, Akhtaruzzaman AKM. Efficacy of amitriptyline and duloxetine in post-chikungunya neuropathic pain; a randomized, open-label, cross-over clinical trial. Anaesth Pain Intensive Care. 2021;25(5):647–52.